<DOC>
	<DOC>NCT00657319</DOC>
	<brief_summary>This observational study is conducted in Europe. The objective of this retrospective observational cohort analysis is to assess the changes of glycaemic control and quality of care in those Type 2 diabetic patients who were previously treated with Mixtard速 insulins after 6 months of their switch to analog premix insulin NovoMix速 30 therapy.</brief_summary>
	<brief_title>Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix速 30 Previously Treated With Mixtard速 Insulins</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin, pork; isophane insulin, pork drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Subjects diagnosed with type 2 diabetes previously treated with BHI for at least 12 months Analogue premix administration for the last 6 months Known or suspected allergy to insulin aspart Newly diagnosed diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>